147 related articles for article (PubMed ID: 33028757)
1. Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia.
Baba N; Kameda H; Nakamura A; Yong Cho K; Nomoto H; Mitsuhashi T; Miyoshi H; Atsumi T
Endocr J; 2021 Feb; 68(2):195-200. PubMed ID: 33028757
[TBL] [Abstract][Full Text] [Related]
2. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
3. Expression of FOXL2 in human normal pituitaries and pituitary adenomas.
Egashira N; Takekoshi S; Takei M; Teramoto A; Osamura RY
Mod Pathol; 2011 Jun; 24(6):765-73. PubMed ID: 21478824
[TBL] [Abstract][Full Text] [Related]
4. Pit-1 gene expression in human pituitary adenomas using the reverse transcription polymerase chain reaction method.
Yamada S; Takahashi M; Hara M; Hattori A; Sano T; Ozawa Y; Shishiba Y; Hirata K; Usui M
Clin Endocrinol (Oxf); 1996 Sep; 45(3):263-72. PubMed ID: 8949563
[TBL] [Abstract][Full Text] [Related]
5. Clinical Relevance and Immunohistochemical Patterns of Silent Pituitary Adenomas: 10 Years of Single-centre Experience.
Akkus G; Karagun B; Çetinalp NE; Açıkalın A; Evran M; Sengöz S; Sert M; Zorludemir S; Tetiker T
Curr Med Imaging; 2021; 17(2):310-317. PubMed ID: 33357196
[TBL] [Abstract][Full Text] [Related]
6. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
[TBL] [Abstract][Full Text] [Related]
7. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
8. Suprasellar pituitary adenomas: a 10-year experience in a single tertiary medical center and a literature review.
Zhu J; Wang Z; Zhang Y; Liu J; Li X; Deng K; Lu L; Yao Y
Pituitary; 2020 Aug; 23(4):367-380. PubMed ID: 32378170
[TBL] [Abstract][Full Text] [Related]
9. GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas.
Sanno N; Teramoto A; Matsuno A; Takekoshi S; Osamura RY
J Clin Endocrinol Metab; 1995 Aug; 80(8):2518-22. PubMed ID: 7543115
[TBL] [Abstract][Full Text] [Related]
10. Composite somatotroph--ACTH-immunoreactive pituitary adenoma with transformation of hyperplasia to adenoma.
Mazarakis N; Kontogeorgos G; Kovacs K; Horvath E; Borboli N; Piaditis G
Pituitary; 2001 Sep; 4(4):215-21. PubMed ID: 12501971
[TBL] [Abstract][Full Text] [Related]
11. Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis.
Jahangiri A; Wagner JR; Han SW; Tran MT; Miller LM; Chen R; Tom MW; Ostling LR; Kunwar S; Blevins L; Aghi MK
J Neurosurg; 2016 Mar; 124(3):589-95. PubMed ID: 26252454
[TBL] [Abstract][Full Text] [Related]
12. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
[TBL] [Abstract][Full Text] [Related]
13. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma.
Fernández-Real JM; Engel WR; Simó R; Salinas I; Webb SM
Clin Endocrinol (Oxf); 1998 Jul; 49(1):53-61. PubMed ID: 9797847
[TBL] [Abstract][Full Text] [Related]
14. ACTH response to desmopressin in a patient with acromegaly; expression of corticotropin-releasing factor, urocortins and vasopressin V1b receptor in GH-producing pituitary adenoma.
Arihara Z; Sakurai K; Osaki Y; Fukazawa H; Yamada S; Inoshita N; Murakami O; Ohba K; Takahashi K
Endocr J; 2011; 58(12):1029-36. PubMed ID: 21908929
[TBL] [Abstract][Full Text] [Related]
15. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
[TBL] [Abstract][Full Text] [Related]
16. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
17. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
18. Expression of pituitary homeo box 1 (Ptx1) in human non-neoplastic pituitaries and pituitary adenomas.
Tahara S; Kurotani R; Sanno N; Takumi I; Yoshimura S; Osamura RY; Teramoto A
Mod Pathol; 2000 Oct; 13(10):1097-108. PubMed ID: 11048804
[TBL] [Abstract][Full Text] [Related]
19. Subclinical hyperfunctioning pituitary adenomas: the silent tumors.
Cooper O; Melmed S
Best Pract Res Clin Endocrinol Metab; 2012 Aug; 26(4):447-60. PubMed ID: 22863387
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical studies on human pituitary gland and adenomas.
Kasper M; Kasper M; Kern F; Heitz PU; Gudat F
J Hirnforsch; 1991; 32(6):725-34. PubMed ID: 1821419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
